DC CFAR Member, Matthew Levy, along with his colleagues from GW and the DC DOH, has recently published an article in PLOS One entitled, "Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis".
The article explores the willingness of community-recruited men who have sex to use long-acting injectable pre-exposure prophylaxis (PrEP) for HIV prevention. Although long-acting injectable formulations of PrEP are currently being studied and not yet FDA-approved, this study is one of the first to assess the acceptability and willingness to use long-acting injectable agents for PrEP among men who have sex with men, should they become available on the market. The research discussed offers insight into the level of interest in LAI PrEP among MSM and can inform strategies for scaling up LAI PrEP to target populations if it is found to be safe and efficacious.
Click here to read the full article.